ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Valencia, VC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Valencia, VC, ESP:

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

This study is researching an investigational drug called linvoseltamab ("study drug") in participants at high risk of developing multiple my ...

Enrolling
Smoldering Multiple Myeloma (SMM)
Drug: Linvoseltamab

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Valencia, Spain and 13 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Active, not recruiting
Multiple Myeloma
Drug: Carfilzomib
Drug: CC-92480

Phase 1, Phase 2

Celgene
Celgene

Valencia, Spain and 48 other locations

Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood s...

Active, not recruiting
Smoldering Multiple Myeloma
Drug: Lenalidomide
Drug: carfilzomib

Phase 2

PETHEMA Foundation

Valencia, Spain and 15 other locations

after Intensification therapy) and safety of Tec-Dara (Teclistamab+Daratumumab) and Tal-Dara (Talquetamab+Daratumumab) in de novo high-risk multiple...

Enrolling
High-Risk de Novo Multiple Myeloma
Drug: Teclistamab
Drug: Lenalidomide

Phase 2

PETHEMA Foundation

Valencia, Spain and 9 other locations

versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Daratumumab

Phase 3

Stichting European Myeloma Network

Valencia, Spain and 126 other locations

with BMS-986405 in participants with relapsed and refractory multiple myeloma (MM). The dose escalation part (Part A) of the study ...

Active, not recruiting
Multiple Myeloma
Drug: CC-99712
Drug: BMS-986405

Phase 1

Celgene
Celgene

Valencia, Spain and 19 other locations

provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding o ...

Active, not recruiting
Multiple Myeloma
Drug: Elranatamab (PF-06863135)

Phase 2

Pfizer
Pfizer

Valencia, Spain and 77 other locations

monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...

Enrolling
Multiple Myeloma
Drug: Elranatamab
Drug: Lenalidomide

Phase 3

Pfizer
Pfizer

València, Spain and 210 other locations

escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: CC-93269

Phase 1

Celgene
Celgene

Valencia, Spain and 34 other locations

with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM).All eligible subjects must be previously treate...

Active, not recruiting
Multiple Myeloma
Drug: CC-92480
Drug: Dexamethasone

Phase 1, Phase 2

Celgene
Celgene

Valencia, Spain and 53 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems